Nemaura Medical Overview
Valuation check: NMRD's ROE is 35.32%, above the Healthcare sector average of -75.59%.
Get informed when a big investor buys or sells
+ Follow35.32%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Nemaura Medical (NMRD) currently reports a ROE of 35.32%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Nemaura Medical's ROE history and peer comparisons.
Nemaura Medical's ROE of 35.32% is higher than the Healthcare sector average of -75.59%. That is roughly 146.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Nemaura Medical's current 35.32% should be judged against Healthcare norms (sector average: -75.59%) and against NMRD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 35.32%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Nemaura Medical, and consider following NMRD for alerts when major investors trade the stock.
Nemaura Medical is classified in the Healthcare sector. On ROE, it currently shows 35.32% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NMRD with unrelated industries.
